Seeking to encourage drug companies to conduct more clinical trials of innovative medicines in China, the Chinese government has proposed new protections on pharmaceutical data. Under the draft proposal, the China Drug Administration (CDA) would expand data exclusivity—the protection of clinical data... Read More
In May, the Chinese government published its first national list of rare diseases, a welcome development for foreign pharmaceutical companies eager to market treatments for their products there. The list of 121 diseases identified as rare was published by five Chinese government... Read More
Chronic obstructive pulmonary disease (COPD) is more prevalent in China than anywhere else in the world, afflicting more than 8.6% of adults, according to a new study by researchers at Tulane University. Almost 100 million people in China suffer from the group... Read More
The Trump administration’s first set of tariffs, which will affect about $800 million worth of imported medical devices and components, will be imposed on July 6, 2018. According to Minnesota’s Star Tribune, for many Minnesota medtech companies, China is the largest global... Read More
China’s Center for Medical Device Evaluation (CMDE) has issued a new draft guidance for obtaining approval of 3D-printed medical devices, as the nation’s regulatory authorities focus new attention on the fast-developing field of 3D printing technology. The guidance, proposed by the agency... Read More
Seeking to counter the country’s growing reliance on foreign drug imports, China’s government is planning massive investment in its own pharmaceutical industry over the next seven years. Chinese pharmaceutical giants most likely to benefit from the plan include Jiangsu Hengrui Medicine, CSPC... Read More
Pushing to offer more timely healthcare to its 1.4 billion people, the Chinese government is encouraging its top tier hospitals to offer online services that would allow patients to make appointments, receive test results, and consult with doctors over the Internet. The... Read More
China’s in vitro diagnostics (IVD) market is growing at an annual rate of 13.2% and is projected to reach a valuation of $5.9 billion by 2022. China represents one of the largest clinical laboratory markets in the Asia-Pacific region, and the fastest... Read More
This article was originally published on MedTech Intelligence. Driven largely by hepatitis in its various forms, liver disease has long been a fixture of life in China and Southeast Asia. Over the past three decades, public health programs in the region have... Read More
In March 2018, Chinese Premier Li Keqiang announced that China will reduce tariffs on imported cancer drugs to zero percent. The plan should give a boost to global drug makers such as AstraZeneca, Novartis, Pfizer, and Roche by making their treatments more... Read More